GlassScriptPhysician profile
Daniel A Jones
NPI 1376507293
$11,332.16
in general payments reported to CMS, 2019-2025
48 companies · $15.11 in 2025
The $15.11 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,864 · 2020: $1,174 · 2021: $6,536 · 2022: $942 · 2023: $624 · 2024: $177 · 2025: $15.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $5,000.00 | 2021 | |
| Supernus Pharmaceuticals, INC. | $1,026.01 | 2019-2024 | Qelbree, Qelbree |
| Sk Life Science, INC. | $473.42 | 2020-2024 | |
| Greenwich Biosciences, INC. | $444.69 | 2019-2021 | |
| Eisai INC. | $380.50 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $353.56 | 2019-2020 | |
| Ucb, INC. | $337.67 | 2019-2022 | |
| Abbvie INC. | $330.55 | 2021-2024 | |
| Mdd US Operations, LLC | $310.39 | 2019-2024 | Gocovri, Gocovri |
| Sunovion Pharmaceuticals INC. | $226.56 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $216.46 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.28 | 2019-2023 | Trintellix |
| Jazz Pharmaceuticals INC. | $181.69 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $155.86 | 2021 | |
| Argenx US, INC. | $143.68 | 2022-2023 | Vyvgart |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.